Phase I Study of the Hypomethylating Drug SGI-110 Plus Cisplatin in Relapsed Refractory Germ Cell Tumors
Phase of Trial: Phase I
Latest Information Update: 21 Feb 2018
At a glance
- Drugs Guadecitabine (Primary) ; Cisplatin
- Indications Germ cell and embryonal neoplasms
- Focus Adverse reactions
- 15 Feb 2018 Planned End Date changed from 31 Dec 2018 to 31 Dec 2019.
- 15 Feb 2018 Planned primary completion date changed from 31 Dec 2017 to 31 Dec 2018.
- 29 Aug 2017 Status changed from suspended to recruiting.